Novartis presents latest Phase III Fabhalta®

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.

Related Keywords

Denmark , Stockholm , Sweden , United States , Praga , Praha , Hlavníesto , Czech Republic , Switzerland , Danish , America , Imke Kappes , Jonathan Graham , Marlena Abdinoor , David Kavanagh , Nicole Zinsli Somm , Parag Mahanti , Marianne Silkj , Satoshi Sugimoto , David Soergel , Isabella Zinck , Sloan Simpson , Michael Meo , Exchange Commission , University Of Washington , Facebook , Metabolism Development Unit , Faculty Of Medical Sciences At Newcastle University , Novartis , European Renal Association , Linkedin , Glomerular Diseases Work Group , G Steering Committee Member , Instagram , Professor David Kavanagh , Complement Therapeutics , Honorary Consultant Nephrologist , Medical Sciences , Newcastle University , Steering Committee , Global Head , Parallel Group , Placebo Controlled Study , Accessed May , Complement Pathway Inhibition , Study Design , Kidney Int , Narrative Review , Rare Renal , Intj Mol , Dense Deposit , Rare Complement Driven Renal , Nat Rev , Hemolytic Uremic Syndrome , Improving Global , Improving Global Outcomes , Glomerular Diseases Work , Practice Guideline , Iga Nephropathy , Interim Results , Primary Iga Nephropathy Patients , Open Label Trial , Evaluate Efficacy , Twice Daily , Who Are Naive , Complement Inhibitor Therapy , Surrogate End Point , Clinj Am Soc , Kidney Outcomes , Nephrol Dial , Endpoint Analysis , Atrasentan Shows Significant Reduction , Primary Iga Nephropathy , Interim Analysis Results , Long Term Safety , Month Extension Study Data , Patients Enrolled , Good Tolerability , Dose Exploration , Placebo Controlled , Multicenter Phase , Oral Corticosteroids , Active Lupus Nephritis Class , Clinicopathologic Features , Genetic Complement Abnormalities Play , Critical Role , Dense Deposit Disease , Immune Complex ,